Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net revenue increased 62% ...

The company said, “Coherus projects post-UDENYCA-close cash of approximately $250 million and cash runway projections exceeding two years, past ...

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Coherus BioSciences Inc. (CHRS) on Monday reported a loss of $50.7 million in its fourth quarter. On a per-share basis, the Redwood City, ...

Please proceed. Thank you, Carmen. Good afternoon and welcome to Coherus BioSciences fourth quarter and full year 2024 earnings conference call. Joining me today to discuss our results are Denny ...

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Coherus BioSciences Inc. (CHRS) on Monday reported a loss of $50.7 million in its fourth quarter. On a per-share basis, the Redwood City ...

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Coherus BioSciences Inc. (CHRS) on Monday reported a loss of $50.7 million in its fourth quarter. The Redwood City, California-based ...

Coherus BioSciences (NASDAQ:CHRS – Get Free Report) is expected to be issuing its quarterly earnings data before the market ...

Projected Cash Post-Divestiture: $250 million on the balance sheet. Coherus BioSciences Inc (NASDAQ:CHRS) successfully executed its four-part strategy in 2024, including driving top-line revenues ...